Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor
19 Novembro 2020 - 10:00AM
Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company
focused on developing gene therapies to radically transform the
lives of patients with neurodegenerative diseases, today announced
the appointment of Guangping Gao, Ph.D., as Chief AAV Scientific
Advisor. Dr. Gao, a world-recognized scientist and past President
of the ASGCT, has played key roles in the discovery and
characterization of adeno-associated virus (AAV) serotypes which
were instrumental in the resurgence of gene therapy. In his
advisory role, Dr. Gao will provide strategic guidance and
scientific and technical input across Sio’s AAV-based gene therapy
programs.
“We are honored to welcome Dr. Gao, a gene
therapy pioneer, to Sio Gene Therapies,” said Pavan Cheruvu, M.D.,
Chief Executive Officer of Sio. “Dr. Gao brings an incredible
wealth of knowledge ranging from fundamental discoveries in viral
vectors, preclinical and clinical gene therapy product development,
to viral manufacturing for clinical research. We believe his
experience and insight will be invaluable to our team as we
continue to advance our pipeline and evaluate potential business
development opportunities. We look forward to collaborating with
Dr. Gao as we work toward our mission of providing transformative
treatments to patients with severe genetic disease.”
Dr. Gao said, “Sio’s strategic approach to gene
therapy directly targets the underlying disease biology, which I
believe has the potential to lead to transformative and life-saving
treatments. I have been impressed by the team’s comprehensive
execution in driving forward clinical programs while in parallel
laying a strong manufacturing foundation to support their mission
to deliver these treatments to patients as rapidly as possible. I
am thrilled to begin my role at Sio and look forward to leveraging
my diverse experiences to fully unlock the potential of their gene
therapy portfolio."
Dr. Gao is Co-Director of the Li Weibo Institute
for Rare Disease Research, Director of the Horae Gene Therapy
Center and Viral Vector Core, Professor of Microbiology and
Physiological Systems and Penelope Booth Rockwell Professor in
Biomedical Research at the University of Massachusetts Medical
School. Dr Gao’s more than 30 years in scientific research in
molecular genetics have made foundational contributions to the
development of viral vector gene therapy for rare genetic diseases
including the discovery, development and engineering of novel viral
vectors for in vivo gene delivery as well as preclinical and
clinical gene therapy product development. He has also made
significant contributions to the development of viral vector
manufacturing for gene therapy applications and the development of
technology platforms for novel gene therapy approaches in humans.
Dr. Gao has published nearly 300 research papers and serves as the
Executive Editor-In-Chief of Human Gene Therapy, Senior Editor of
the Gene and Cell Therapy book series and serves on the Editorial
Boards of several other gene therapy and virology journals. In
addition to previously serving as President of ASGCT, he is an
elected fellow of the U.S. National Academy of Inventors, holding
174 patents and an additional 373 patent applications pending with
over 10 licensed to pharmaceutical companies. Dr. Gao is co-founder
of Voyager Therapeutics, Adrenas Therapeutics and Aspa
Therapeutics.
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science
with bold imagination to develop genetic medicines that aim to
radically improve the lives of patients. Our current pipeline of
clinical-stage candidates includes the first potentially curative
AAV-based gene therapies for GM1 gangliosidosis and
Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal
pediatric conditions caused by single gene deficiencies. We are
also expanding the reach of gene therapy to highly prevalent
conditions such as Parkinson’s disease, which affects millions of
patients globally. Led by an experienced team of gene therapy
development experts, and supported by collaborations with premier
academic, industry and patient advocacy organizations, Sio is
focused on accelerating its candidates through clinical trials to
liberate patients with debilitating diseases through the
transformational power of gene therapies. For more information,
visit www.siogtx.com.
Forward-Looking Statements
This press release contains forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as "will," "expect,"
"believe," "estimate," and other similar expressions are intended
to identify forward-looking statements. For example, all statements
Sio makes regarding costs associated with its operating activities
are forward-looking. All forward-looking statements are based on
estimates and assumptions by Sio’s management that, although Sio
believes to be reasonable, are inherently uncertain. All
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those that
Sio expected. Such risks and uncertainties include, among others,
the impact of the Covid-19 pandemic on our operations, the
initiation and conduct of preclinical studies and clinical trials;
the availability of data from clinical trials; the development of a
suspension-based manufacturing process for Axo-Lenti-PD; the
scaling up of manufacturing, the expectations for regulatory
submissions and approvals; the continued development of our gene
therapy product candidates and platforms; Sio’s scientific approach
and general development progress; and the availability or
commercial potential of Sio’s product candidates. These statements
are also subject to a number of material risks and uncertainties
that are described in Sio’s most recent Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on November
13, 2020, as updated by its subsequent filings with the Securities
and Exchange Commission. Any forward-looking statement speaks only
as of the date on which it was made. Sio undertakes no obligation
to publicly update or revise any forward-looking statement, whether
as a result of new information, future events or otherwise.
Contacts:
Media and Investors
Parag MeswaniSio Gene Therapies, Inc.Chief Commercial
Officerinvestors@siogtx.com
Josephine Belluardo, Ph.D. LifeSci Communications(646)
751-4361jo@lifescicomms.cominfo@siogtx.com
Axovant Gene Therapies (NASDAQ:AXGT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024